Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT05225558
Other study ID # LCB35-0371-21-2-01
Secondary ID
Status Terminated
Phase Phase 2
First received
Last updated
Start date April 26, 2022
Est. completion date February 16, 2024

Study information

Verified date January 2024
Source LigaChem Biosciences, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objectives of this study is to exploratory whether vancomycin + delpazolid is more effective to the standard of treatment (vancomycin)/ for hospitalised adults with MRSA bacteraemia.


Description:

The mortality from S aureus bacteremia is higher for MRSA than for methicillin-susceptible S aureus (MSSA), typically at 20% to 25%. The current standard therapy for MRSA bacteremia is vancomycin. Vancomycin has many shortcomings, including poor tissue penetration and slow killing time. Vancomycin has reduced efficacy against MRSA and tended to increase the MIC level (called MIC creep). Addition of Delpazolid to Vancomycin could improve the known drawbacks of Vancomycin alone.


Recruitment information / eligibility

Status Terminated
Enrollment 40
Est. completion date February 16, 2024
Est. primary completion date February 16, 2024
Accepts healthy volunteers No
Gender All
Age group 19 Years and older
Eligibility Inclusion Criteria: - Male or female =19 years of age on the date of written consent - Subject who has confirmed positive MRSA at least one set of blood cultures within 72 hours prior to randomization OR, Subject who has confirmed positive MRSA at least one set of blood culture whthin 96 hours prior to randomization and treated with vancomycin at least 72 hours prior to randomization - Subject who has clinical symptoms or signs of MRSA bacteremia according to the judgment of the investigator - Subject who voluntarily decides to participate in this clinical trial after being explained fully, and agrees in writing to implement the clinical trial compliance matters Exclusion Criteria: - Subject with polymicrobial bacteremia or infections including Gram-negative strain - Subject undergoing or in need of treatment with antiviral or antifungal drugs - Subject who has received treatment for MRSA bacteremia within 3 months of screening (Subjects who have "re-infection" by investigator's judgement may participant in the study.) - Subject who has been administered effective antibiotics against MRSA (Vancomycin, etc.) for more than 96 hours prior to the first investigational product administration. (However, antibiotics effective for MRSA such as vancomycin are allowed to be administered for less than 72 hours.) - Septic shock patients - Subject who has hypersensitivity to vancomycin or linezolid - Subject who has a history of hypersensitivity to peptide-based antibiotics and aminoglycoside-based antibiotics - Subject who is receiving a MAO inhibitor(MAOI) or has received MAOI within 14 days of the first investigational drug administration - Subject taking serotonin reuptake inhibitors, tricyclic antidepressants, serotonin 5-HT1 receptor agonists (triptan), meperidine, or buspirone - Subject with severely decreased immunity (Severe neutropenia (ANC <0.5×10^9/L) etc.) - Subject who is expected to die within 2 days due to serious complications of MRSA bacteremia based on the judgment of the investigator - Body Mass Index (BMI) =35 kg/m2 - Subject who is unable to administer drugs orally - Pregnant or lactating female, female or male with childbearing potential who disagrees with the use of appropriate contraceptive methods during the study and up to 14 days after the last dose of the investigator product - Subject who has received other clinical trial drugs within 30 days of screening - Subject who is not suitable for participation in this clinical trial according to the medical findings of investigators

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Delpazolid
BID, PO
Vancomycin
IV infusion per 2020 IDSA guideline
Placebo of Delpazolid
BID, PO

Locations

Country Name City State
Korea, Republic of Korea University Ansan Hospital Ansan
Korea, Republic of Chosun University Hospital Gwangju
Korea, Republic of Asan Medical Center Seoul
Korea, Republic of Seoul National University Bundang Hospital Seoul
Korea, Republic of Severance Hospital Seoul

Sponsors (1)

Lead Sponsor Collaborator
LigaChem Biosciences, Inc.

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Other Vancomycin minimum inhibitory concentration (MIC) levels Vancomycin MIC level up to 6 weeks
Other Delpazolid MIC levels Delpazolid MIC level by BMD up to 6 weeks
Other Pharmacokinetics (PK) parameters: Cmax Peak Plasma Concentration (Cmax) up to 6 weeks
Other Pharmacokinetics (PK) parameters: AUC(0-last) the area under the concentration-time curve from dosing (time 0) to the time of the last measured concentration up to 6 weeks
Other Pharmacokinetics (PK) parameters: Half-life Half-life up to 6 weeks
Other Pharmacokinetics (PK) parameters: Tmax time to reach Cmax up to 6 weeks
Other Pharmacokinetics (PK) parameters: Cl Clearance up to 6 weeks
Primary Overall cure rate by Day 14 (composite response rate: clinical improvement plus clearance of bacteremia) 'Overall cure' means that there are no symptoms of infection that existed when enrolled in the clinical trial, there are no new metastatic infection due to MRSA and no new infection (clinical improvement), and MRSA negative is confirmed twice in a row as a result of blood culture tests ( clearance of bacteremia).
a. If negative in the blood culture test is confirmed for the first time, additional test will be performed the next day, and if it results negative for a total of two times in a row, it is judged as 'clearance of bacteremia'.
by Day 14
Secondary Overall cure rate by End of Treatment (EOT) composite response rate: clinical improvement plus clearance of bacteremia by EOT visit (up to 6 weeks)
Secondary Mortality due to MRSA bacteremia Proportion of subjects who died due to MRSA bacteremia by Test of Cure (TOC) (=4 weeks after EOT (up to 6 weeks))
Secondary Microbiological relapse rate Defined as a positive blood culture to MRSA when previous ones were negative by TOC (=4 weeks after EOT)
Secondary Clearance of MRSA bacteremia rate Proportion of subjects who confirmed MRSA negative two consecutive set in the blood culture test Day 3, Day 5, Day 7, Day 14, EOT (up to 6 weeks)
Secondary Persistent MRSA bacteremia rate Proportion of subjects who have positive results on blood culture tests Day 3, Day 5, Day 7, Day 14
Secondary Time to clearance of MRSA bacteremia If negative in the blood culture test is confirmed for the first time, additional test will be performed the next day, and if it results negative for a total of two times in a row, it is judged as clearance of bacteremia. The period until the clearance of bacteremia is defined as the period (day) from the date of the first blood culture test within 72 hours prior to randomization with MRSA positive (index blood culture) to the date of the blood culture test with the first negative result confirmed. by EOT (up to 6 weeks)
See also
  Status Clinical Trial Phase
Completed NCT03096405 - Impact MRSA -PCR on Patient Management N/A
Recruiting NCT06069206 - Effect of Direct-from-blood Bacterial Testing on Antibiotic Administration and Clinical Outcomes N/A
No longer available NCT04597242 - Expanded Access Study of Exebacase in COVID-19 Patients With Persistent MRSA Bacteremia